ArticleNeuro-oncology advances
Genomic and clinical determinants of local and distant intracranial progression following surgical resection of brain metastases.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of molecular alterations in predicting local and distant progression following brain metastasis resection is poorly understood. In this study, we investigated clinical and molecular predictors of intracranial progression following brain metastasis resection. Methods: A retrospective analysis of 228 patients who underwent brain metastasis resection at the University of Pittsburgh Medical Center was performed. Tumor specimens underwent next-generation sequencing using the UPMC Oncomine Comprehensive Assay. Bootstrap forest analysis was used to identify top genetic predictors by variable importance for local and distant progression. Cox proportional hazards models were used to identify independent predictors. Results: Local progression occurred in 110 patients (48.2%) and distant progression in 98 patients (43%). The most frequent genetic alterations were TP53 mutations (61.6%), KRAS mutations (31.2%), and CDKN2A/B copy number alterations (24.6%, 23.2%). For local progression, bootstrap forest analysis identified PTEN, STK11, KRAS, FGF3, and ATM alterations as top predictors. On multivariable analysis adjusting for primary malignancy type, independent predictors of local progression included RB1 mutations (HR 3.03, Conclusion: These findings suggest that integrating molecular profiling with clinical factors may contribute to intracranial progression risk stratification after brain metastasis resection, though expansion of the dataset with histology-stratified analyses is warranted to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.